Key Takeaways:
The European Commission approved AbbVie's RINVOQ for severe alopecia areata in patients 12 and older, based on Phase 3 data showing 80% scalp hair coverage at week 24.
"The European Commission's approval of RINVOQ provides a new treatment option for the severe alopecia areata community in the EU with demonstrated scalp regrowth, including complete scalp hair regrowth for some, that can support management of the disease," Roopal Thakkar, executive vice president, research and development and chief scientific officer at AbbVie, said.
The approval covers 15 mg and 30 mg once-daily doses of upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie scientists. In two replicate Phase 3 studies from the UP-AA clinical program, both doses met the primary endpoint of a Severity of Alopecia Tool score of 20 or less at week 24, meaning at least 80% scalp hair coverage. RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth, defined as a SALT score of zero, versus placebo at week 24. Key secondary endpoints were also met, including improvements in eyebrows and eyelashes. The trials randomized 1,399 participants ages 12 to 64 across 248 sites worldwide.
Alopecia areata is an autoimmune disease that causes unpredictable hair loss patterns, from round bald patches to complete loss of all body hair. Despite its immune-mediated nature, the condition is often misunderstood as a cosmetic problem. Patients face up to 40% higher risk of new-onset depression and anxiety compared with the general population, according to a population-based study, with the risk increasing in women. RINVOQ is already approved in the EU for atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, Crohn's disease, vitiligo and giant cell arteritis. The drug is also under review by the US Food and Drug Administration for alopecia areata.
The approval expands RINVOQ's addressable market into a new autoimmune indication with high unmet need, adding to a portfolio that already treats 19 immune-mediated diseases across more than 175 countries. Investors will watch for the FDA's decision on the same indication, which could open the US market, the world's largest pharmaceutical market by revenue.
This article is for informational purposes only and does not constitute investment advice.
